Myriad Genetics MYGN (news,
chart,
quote) - MYGN volatility Up into Alzheimer
MYGN is recently down $1.38 to $46.60 in pre-open trading. MYGN's Flurizan, a treatment for Alzheimer's diseases, had negative Phase 3 results. MYGN July option implied volatility of 102 was above its 6-month average of 71 according to Track Data.
DISCLAIMER: RED Option, in an attempt to provide the best resources from some of the industry's most capable people, has introduced our Market Minute commentary. RED Option does not endorse this commentary or information as trade recommendations nor does it have any input whatsoever into the decision making. Any content for the Market Minute is the sole opinion of the author.
